Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity

Clinical and Experimental Allergy

Volumn 35, Issue 1, 2005, Pages 97-103

  Tamura, Tadafumi ^a   Matsubara, M ^a   Hasegawa, K ^a   Ohmori, K ^a   Karasawa, A ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Animal model; Antihistamine; Atopic dermatitis; Olopatadine hydrochloride; Rebound phenomenon; Topical steroid

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; NERVE GROWTH FACTOR; OLOPATADINE; OXAZOLONE; PREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REBOUND; RELAPSE; SKIN ALLERGY; TREATMENT WITHDRAWAL;

ANIMALS; CHRONIC DISEASE; DERMATITIS, CONTACT; DIBENZOXEPINS; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS; INTERLEUKIN-4; MALE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; PREDNISOLONE; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 13244291455     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2005.02147.x     Document Type: Article

References (29)

1. Wahlgren CF. Itch and atopic dermatitis. J Dermatol 1999; 26:770-9.
2. Guidelines for therapy for atopic dermatitis 2003. Jpn J Dermatol 2003; 1:451-7.
3. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4:1-191.
4. Hiratsuka S, Yoshida A, Ishioka C et al. Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis. J Allergy Clin Immunol 1996; 98:107-13.
5. Kawakami T, Soma Y, Morita E et al. Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology 2001; 203:32-7.
6. Fukaya M. Improvement of atopic dermatitis after discontinuation of topical corticosteroid treatment. Arch Dermatol 2000; 136:679-80.
7. Leung DYM. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999; 104:99-108.
8. Herz U, Bunikowski R, Renz H. Role of T cells in atopic dermatitis. Int Arch Allergy Immunol 1998; 115:179-90.
9. Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine gene expression in acute vs. chronic atopic dermatitis. J Clin Invest 1994; 94:870-6.
10. Pastore S, Fanales-Belasio E, Albanesi C et al. Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis: implications for sustained dendritic cell activation in the skin. J Clin Invest 1997; 99:3009-17.
11. Wang B, Amerio P, Sauder DN. Role of cytokines in epidermal Langerhans cell migration. J Leukoc Biol 1999; 66:33-9.
12. Uchi H, Terao H, Koga T et al. Cytokines and chemokines in the epidermis. J Dermatol Sci 2000; 24:S29-38.
13. Tanaka T, Tsutsui H, Yoshimoto T et al. Interleukin-18 is elevated in the sera from patients with atopic dermatitis and from atopic dermatitis model mice, NC/Nga. Int Arch Allergy Immunol 2001; 125:236-40.
14. Ruzicka T, Gluck S. Cutaneous histamine levels and histamine releasability from the skin in atopic dermatitis and hyper-IgE-syndrome. Arch Dermatol Res 1983; 275:41-4.
15. Horsmanheimo L, Harvima IT, Jarvikallio A et al. Mast cells are one major source of IL-4 in atopic dermatitis. Br J Dermatol 1994; 131:348-53.
16. Gibbs BF, Wierecky J, Welker P et al. Human skin mast cells rapidly release preformed and newly generated TNF-α and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol 2001; 10:312-20.
17. Webb EF, Tzimas MN, Newsholme SJ et al. Intralesional cytokines in chronic oxazolone-induced contact sensitivity suggest roles for tumor necrosis factor α and interleukin-4. J Invest Dermatol 1998; 111:86-92.
18. Kitagaki H, Ono N, Hayakawa K et al. Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile. J Immunol 1997; 159:2484-91.
19. Ohmori K, Hayashi K, Kaise T et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol 2002; 88:379-97.
20. Tamura T, Matsubara M, Takada C et al. Effects of olopatadine hydrochloride, an anti-histamine drug, on the skin inflammation induced by repeated topical application of oxazolone in mice. Br J Dermatol 2004; 151:1133-42.
21. Matsubara M, Masaki S, Ohmori K et al. Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophilic leukemia (RBL-2H3) cells. Biochem Pharmacol 2004; 67:1315-26.
22. Hayashi K, Kaise T, Ohmori K et al. Effects of olopatadine hydrochloride on the cutaneous vascular hyperpermeability and the scratching behavior induced by poly-L-arginine in rats. Jpn J Pharmacol 2001; 87:167-70.
23. Kimata H. Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Ann Allergy Asthma Immunol 1999; 82:293-5.
24. Shore PA. The chemical determination of histamine. Methods Biochem Anal 1971; (Suppl.):89-97.
25. Ricci M, Matucci A, Rossi O. IL-4 as a key factor influencing the development of allergen-specific Th2-like cells in atopic individuals. J Invest Allergol Clin Immunol 1997; 7:144-50.
26. Elbe-Burger A, Egyed A, Olt S et al. Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol 2002; 118:767-78.
27. Inoue Y, Isobe M, Shiohara T et al. Inhibitory activity of CX-659S, a novel diaminouracil derivative, against the rebound phenomenon following withdrawal of corticosteroid therapy for chronic contact hypersensitivity responses. Int Arch Allergy Immunol 2003; 131:143-52.
28. Almawi WY, Beyhum HN, Rahme AA et al. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol 1996; 60:563-72.
29. Kohda F, Koga T, Uchi H et al. Histamine-induced IL-6 and IL-8 production are differentially modulated by IFN-γ and IL-4 in human keratinocytes. J Dermatol Sci 2002; 28:34-41.